Fig. 2: Forest plot of mean predicted survival probability and 95% CI – post hoc subgroup analyses by country. | npj Vaccines

Fig. 2: Forest plot of mean predicted survival probability and 95% CI – post hoc subgroup analyses by country.

From: Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Fig. 2

This analysis was based on the pooled data of healthy adults (aged 18-50 years) vaccinated with Ad26.ZEBOV, MVA-BN-Filo in a 56-day interval in five clinical studies (EBL2001, EBL2002, EBL3001, EBL3002, and EBL3003) using a logistic regression model based on NHP data from the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval. Mean predicted survival probability and the 95% bootstrapped CI are reported. CI confidence interval, EU enzyme-linked immunosorbent assay units, GMC geometric mean concentration, N number of participants with data, NHP non-human primate; vertical dashed line = mean predicted survival probability from primary analysis including all participants.

Back to article page